Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer

Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment

(2014) Steven F. Abcouwer et al.   Annals of the New York Academy of Sciences

Genome-wide eQTLs and heritability for gene expression traits in unrelated individuals

(2014) Shengjie Yang et al.   BMC GENOMICS

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

(2014) Sariah Liu et al.   CANCER TREATMENT REVIEWS

Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research

(2014) Xiaowei W. Su et al.   MUSCLE & NERVE

Detection and replication of epistasis influencing transcription in humans

(2014) Gibran Hemani et al.   NATURE

Vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 13 case–control studies

(2014) Yulan Yan et al.   TUMOR BIOLOGY

Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Breast Cancer Risk in a Chinese Population

(2013) Ting Luo et al.   Asian Pacific Journal of Cancer Prevention

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

(2013) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level

(2013) T. Arcondeguy et al.   NUCLEIC ACIDS RESEARCH

Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel

(2013) A K Koutras et al.   PHARMACOGENOMICS JOURNAL

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

(2013) Fotios Loupakis et al.   PLoS One

Genetic Variation in Vascular Endothelial Growth Factor-A and Lung Function

(2012) Angela Simpson et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The single-nucleotide polymorphisms +936 C/T VEGF and −710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population

(2012) Patricia Rodrigues et al.   BREAST CANCER RESEARCH AND TREATMENT

Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis

(2012) L. Eng et al.   CLINICAL CANCER RESEARCH

The Role of Vascular Endothelial Growth Factor A Polymorphisms in Breast Cancer

(2012) Doonyapat Sa-nguanraksa et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiogenesis as a therapeutic target in breast cancer

(2012) Angelos K. Koutras et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Evaluation of Functional Genetic Variants for Breast Cancer Risk: Results From the Shanghai Breast Cancer Study

(2011) B. Zhang et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Mechanisms of resistance to vascular endothelial growth factor blockade

(2011) Shaad E. Abdullah et al.   CANCER

Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: A meta-analysis involving 16,703 individuals

(2011) Kai Wang et al.   CYTOKINE

803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)

(2011) E. Van Cutsem et al.   EUROPEAN JOURNAL OF CANCER

Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis

(2010) Dae Sik Yang et al.   BREAST CANCER RESEARCH AND TREATMENT

VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls

(2010) Dongying Gu et al.   BREAST CANCER RESEARCH AND TREATMENT

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

(2010) Marie-Christine Etienne-Grimaldi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival

(2010) LaCreis R. Kidd et al.   CANCER CAUSES & CONTROL

Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case–control studies

(2010) Liu Liu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment

(2010) Li-Song Teng et al.   Journal of the Chinese Medical Association

Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility

(2010) Li-Xin Qiu et al.   MOLECULAR BIOLOGY REPORTS

Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics

(2010) Cristiane Oliveira et al.   TUMOR BIOLOGY

Bevacizumab in the treatment of breast cancer

(2009) Angelos K. Koutras et al.   CANCER TREATMENT REVIEWS

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

(2009) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

(2009) L. Jain et al.   MOLECULAR CANCER THERAPEUTICS

Discordant somatic and germlineVEGF-Agenotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

(2009) Luigi Coltelli et al.   PHARMACOGENOMICS

Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer

(2009) M. Sheffer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women

(2008) Anna Jakubowska et al.   CANCER LETTERS

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

(2008) H. J. Burstein et al.   CLINICAL CANCER RESEARCH

Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?

(2008) Anna Jakubowska et al.   EUROPEAN JOURNAL OF CANCER

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

(2008) D. G. Nowak et al.   JOURNAL OF CELL SCIENCE

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE